Plexpress and SBW Partner to Offer TRAC Gene Expression Analysis
News May 08, 2012
Plexpress has announced it will partner with SBW to provide SBW’s customers with access to Plexpress’ novel technology.
SBW, a contract research organization serving the drug discovery market, will offer Plexpress’ pre-validated TRAC Cytochrome P450 (CYP) family multiplex assays as part of its portfolio for investigating in vitro drug interactions and pre-clinical ADME-Tox profiles.
Such a service is expected to be very popular, especially given a recent draft report from the FDA, which suggests that drug discovery researchers use CYP mRNA induction, rather than CYP activity, to assess drug metabolism and activity.
TRAC (Transcript Analysis with the aid of Affinity Capture) technology is a new approach to measuring gene expression changes that offers several benefits over qPCR and microarrays, including higher sample throughput and increased assay speed, while simultaneously reducing technical variation.
Genetic Variations in the Lungs Identify COPD RiskNews
Developmental genetic variations in the anatomy of the lung could indicate people at risk of COPD later in life, a study suggests.READ MORE
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE